Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 6 for:    Acalabrutinib | Covid19

Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. (CALAVI US)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04380688
Recruitment Status : Completed
First Posted : May 8, 2020
Results First Posted : September 13, 2021
Last Update Posted : September 13, 2021
Sponsor:
Collaborator:
Acerta Pharma BV
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
CALAVI US will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: Acalabrutinib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Study will consist of two arms Arm 1 is acalabrutinib + best supportive care or Arm 2 is best supportive care alone
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19
Actual Study Start Date : June 13, 2020
Actual Primary Completion Date : November 16, 2020
Actual Study Completion Date : November 16, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Arm 1
Acalabrutinib+ Best Supportive Care
Drug: Acalabrutinib
Acalabrutinib administered orally

No Intervention: Arm 2
Best Supportive Care



Primary Outcome Measures :
  1. Number of Participants With Adverse Events and Serious Adverse Events [ Time Frame: Screening to 28 (+3) days after last dose of acalabrutinib (for acalabrutinib + BSC participants) or to 38 (+3) days after randomization (for BSC alone participants) ]
  2. Percentage of Participants Alive and Free of Respiratory Failure at Day 28 [ Time Frame: At Day 28 ]
    Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by highflow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates >20 L/min with fraction of delivered oxygen ≥0.5) c) Noninvasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation


Secondary Outcome Measures :
  1. Percentage of Participants Alive and Free of Respiratory Failure at Day 14 [ Time Frame: At Day 14 ]
    Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by highflow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates >20 L/min with fraction of delivered oxygen ≥0.5) c) Noninvasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation

  2. Percent Change From Baseline in C-reactive Protein. [ Time Frame: Days 3, 5, 7, 10, 14, 28 ]

    Baseline is defined as the result obtained on the date of randomization. If no result was obtained on the date of randomization, the last result prior to the date of randomization is used.

    Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value.

    The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.


  3. Percent Change From Baseline in Ferritin [ Time Frame: Days 3, 5, 7, 10, 14, 28 ]

    Baseline is defined as the result obtained on the date of randomization. If no result was obtained on the date of randomization, the last result prior to the date of randomization is used.

    Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value.

    The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.


  4. Percent Change From Baseline in Absolute Lymphocyte Count [ Time Frame: Days 3, 5, 7, 10, 14, 28 ]

    Baseline is defined as the result obtained on the date of randomization. If no result was obtained on the date of randomization, the last result prior to the date of randomization is used.

    Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value.

    The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.


  5. Overall Survival [ Time Frame: From randomization until 90 days after randomization. ]
    Median overall survival, calculated using the Kaplan-Meier technique. Confidence interval for median overall survival (days) is derived based on Brookmeyer-Crowley method with log-log transformation.

  6. Percentage of Participants Alive and Discharged From ICU [ Time Frame: At Day 14 and at Day 28 ]
  7. Time From Randomization to First Occurrence of Respiratory Failure or Death on Study Due to Any Cause [ Time Frame: From randomization to 28 days after randomization. ]
    Median time to first occurrence of respiratory failure or death, calculated using the Kaplan-Meier technique. Confidence interval for median overall survival (days) is derived based on Brookmeyer-Crowley method with log-log transformation.

  8. Number of Days Alive and Free of Respiratory Failure [ Time Frame: From randomization to 28 days after randomization. ]
    Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by highflow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates >20 L/min with fraction of delivered oxygen ≥0.5) c) Noninvasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation

  9. Number of Days With Respiratory Failure [ Time Frame: From randomization to 28 days after randomization. ]
    Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by highflow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates >20 L/min with fraction of delivered oxygen ≥0.5) c) Noninvasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation For participants who die (due to any cause) prior to Day 28, days from death to Day 28 are counted as days with respiratory failure. For participants in hospital and experiencing respiratory failure at the time they withdraw from the study, days from last known status to Day 28 are counted as days with respiratory failure.

  10. Number of Days Hospitalized [ Time Frame: From randomization to 28 days after randomization. ]

    For this summary, the hospitalization must be considered clinically indicated to count as a day hospitalized.

    For participants who die (due to any cause) prior to Day 28, days from death to Day 28 are counted as days hospitalized.

    For participants in hospital at the time they withdraw from the study, days from last known status to Day 28 are counted as days hospitalized.


  11. Number of Days in ICU [ Time Frame: From randomization to 90 days after randomization. ]

    For this summary, the ICU stay must be considered clinically indicated to count as a day in ICU.

    For participants who die (due to any cause) prior to Day 90, days from death to Day 90 are counted as days in ICU.


  12. Number of Days Alive Outside of Hospital [ Time Frame: From randomization to 28 days after randomization. ]
  13. Number of Days Alive Outside of Hospital [ Time Frame: From randomization to 90 days after randomization. ]
  14. Percent Change From Baseline in Oxygenation Index [ Time Frame: Days 3, 5, 7, 10, 14, 28 ]

    Baseline is defined as the result obtained on the date of randomization.

    Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value.

    The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.


  15. Time From Randomization to Clinical Improvement of at Least 2 Points on a 9-point Category Ordinal Scale [ Time Frame: From randomization to 28 days after randomization. ]

    9-point category ordinal scale: 0. * Uninfected, no clinical or virological evidence of infection

    1. Ambulatory, no limitation of activities
    2. Ambulatory, limitation of activities
    3. Hospitalized - mild disease, no oxygen therapy
    4. Hospitalized - mild disease, oxygen by mask or nasal prongs
    5. Hospitalized - severe disease, non-invasive ventilation or high flow oxygen
    6. Hospitalised - severe disease, intubation and mechanical ventilation
    7. Hospitalized - severe disease, ventilation and additional organ support, such as pressors, renal replacement therapy, extracorporeal membrane oxygenation
    8. Death

    Median time to first occurrence of respiratory failure or death, calculated using the Kaplan-Meier technique. Confidence interval for median overall survival (days) is derived based on Brookmeyer-Crowley method with log-log transformation.


  16. Pharmacokinetics of Acalabrutinib [ Time Frame: Day 3 and Day 7 ]
    Summary of plasma concentrations (ng/mL) of acalabrutinib

  17. Pharmacokinetics of ACP-5862 [ Time Frame: Day 3 and Day 7 ]
    Summary of plasma concentrations (ng/mL) of ACP-5862



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent or have a legal representative provide consent and authorization to use protected health information (in accordance with national and local patient privacy regulations)
  2. Men and women ≥18 years of age at the time of signing the informed consent form
  3. Confirmed infection with SARS-CoV-2 confirmed per World Health Organization criteria (including positive RT-PCR nucleic acid test)
  4. COVID-19 pneumonia (documented radiographically) requiring hospitalization and oxygen saturation <94% on room air or requires supplemental oxygen
  5. Able to swallow pills
  6. Willing to follow contraception guidelines

Exclusion Criteria:

  1. Respiratory failure at the time of screening due to COVID-19 pneumonia that impedes the ability to swallow pills, or in the opinion of the treating physician, the subject is likely to require mechanical ventilation within the immediate 24 hours and therefore unable to swallow pills.
  2. Known medical resuscitation within 14 days of randomization
  3. Pregnant or breast feeding
  4. Suspected uncontrolled active bacterial, fungal, viral, or other infection (besides infection with SARS-CoV-2)
  5. Alanine aminotransferase (ALT), and/or aspartate aminotransferase (AST) and/or bilirubin ≥ 3x upper limit of normal (ULN) and/or severe hepatic impairment detected during the screening period (per local lab) Exception: AST and/or ALT ≤5 × ULN if considered due to underlying COVID-19 disease, but cannot be associated with concurrent elevated bilirubin (≤2 × ULN).
  6. Uncontrolled or untreated symptomatic arrhythmias, myocardial infarction within the last 6 weeks, or congestive heart failure (NYHA Grade 3 or 4). Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll
  7. Treatment with a strong cytochrome P450 (CYP)3A inhibitor (within 7 days before first dose of study drug) or inducer (within 14 days before first dose of study drug).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04380688


Locations
Layout table for location information
United States, Alabama
Research Site
Anniston, Alabama, United States, 36207
Research Site
Mobile, Alabama, United States, 36604
United States, California
Research Site
Escondido, California, United States, 92029
Research Site
Fullerton, California, United States, 92835
Research Site
Glendale, California, United States, 91206
Research Site
Newport Beach, California, United States, 92663
United States, Connecticut
Research Site
New Haven, Connecticut, United States, 06519
United States, District of Columbia
Research Site
Washington, District of Columbia, United States, 20010
United States, Florida
Research Site
Fort Lauderdale, Florida, United States, 33308
Research Site
Jacksonville, Florida, United States, 32207
Research Site
Jacksonville, Florida, United States, 32209
Research Site
Loxahatchee Groves, Florida, United States, 33470
United States, Indiana
Research Site
Fort Wayne, Indiana, United States, 46804
United States, Kentucky
Research Site
Louisville, Kentucky, United States, 40207
United States, Maryland
Research Site
Annapolis, Maryland, United States, 21401
Research Site
Baltimore, Maryland, United States, 21287
Research Site
Bethesda, Maryland, United States, 20889
Research Site
Bethesda, Maryland, United States, 20892-1374
Research Site
Silver Spring, Maryland, United States, 20910
United States, New Jersey
Research Site
Hackensack, New Jersey, United States, 07601
United States, New York
Research Site
Albany, New York, United States, 12208
Research Site
Bronx, New York, United States, 10467
Research Site
Buffalo, New York, United States, 14263
Research Site
New York, New York, United States, 10029
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States, 19140
United States, Tennessee
Research Site
Nashville, Tennessee, United States, 38120
United States, Texas
Research Site
Houston, Texas, United States, 77030
Research Site
Houston, Texas, United States, 77090
Research Site
Tyler, Texas, United States, 75701
United States, Virginia
Research Site
Richmond, Virginia, United States, 23298
United States, Washington
Research Site
Renton, Washington, United States, 98055
Sponsors and Collaborators
AstraZeneca
Acerta Pharma BV
  Study Documents (Full-Text)

Documents provided by AstraZeneca:
Study Protocol  [PDF] July 24, 2020
Statistical Analysis Plan  [PDF] October 1, 2020

Additional Information:
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT04380688    
Other Study ID Numbers: D822FC00003
First Posted: May 8, 2020    Key Record Dates
Results First Posted: September 13, 2021
Last Update Posted: September 13, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access Criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
URL: https://astrazenecagroup-dt.pharmacm.com/DT/Home

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AstraZeneca:
2019 novel coronavirus disease
Acalabrutinib
Btk inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Acalabrutinib
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Antineoplastic Agents